Our novel assets under development combine early and advanced stage programs. Our developments in novel biologics is our foray into the biosimilars segment. We are the pioneers in developing, manufacturing and launching BIOMAb-EGFR®, India’s first indigenously produced novel monoclonal antibody for the treatment of head and neck cancer; and ALZUMAb™, the world’s first novel anti-CD6 monoclonal antibody in India, for psoriasis.
CONTACT
Group Companies
BIOCON AND NOVELS
Biocon & Novels
Addressing unmet needs in diabetes, cancer and autoimmune conditions
Our developments in novel biologics is our foray into the biosimilars segment.
Our approach receives the financial and scientific participation of credible organisations like JDRF (U.S.) for the development of Insulin Tregopil, as a treatment for Type 1 diabetes.
Novels Portfolio
Our current novels portfolio acquired through early stage partnerships include:
An oral insulin molecule
Monoclonal antibodies against novel targets like CD6, against established targets like CD20 and EGFR
A pipeline of bispecific fusion antibodies that exploit the recent understanding of the role of checkpoint inhibitors
Our data is garnering a great deal of licensing and partnering interest. Our approach receives the financial and scientific participation of credible organisations like JDRF (U.S.) for the development of Insulin Tregopil, as a treatment for Type 1 diabetes. Such partnerships help mitigate our financial exposure in these high risk but high reward initiatives.
Novels Biologics
A rigorous valuation of their ‘functional activities’ and ‘mechanism of action’ helps us map the progress of our programs. Our skills in manufacturing processes, analytical development and cutting-edge translational and clinical sciences enable us to maximise the overall probability of success.
Know more
about us
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
